[EN] NANOPARTICLE FORMULATION OF BCL-2 INHIBITOR<br/>[FR] FORMULATION DE NANOPARTICULES D'INHIBITEUR DE LA BCL-2
申请人:RECURIUM IP HOLDINGS LLC
公开号:WO2021007303A1
公开(公告)日:2021-01-14
Various albumin nanoparticle Bcl-2 inhibitor formulations are described, along with methods of using them to treat conditions characterized by excessive cellular proliferation, such as cancer and tumors. In various embodiments, such Bcl-2 inhibitor formulations contain albumin and a compound of the following Formula (I), or a pharmaceutically acceptable salt thereof, where the variables in Formula (I) are defined herein.
A series of substituted 4,6-dihydrospiro[[1,2,3]triazolo[4,5-b]pyridine-7,3′-indoline]-2′,5(3H)-dione analogues, the use thereof and the preparation thereof.
2-SUBSTITUTED PYRAZOLE AMINO-4-SUBSTITUTED AMINO-5-PYRIMIDINE FORMAMIDE COMPOUND, COMPOSITION, AND APPLICATION THEREOF
申请人:Beijing Scitech-MQ Pharmaceuticals Limited
公开号:EP3686197A1
公开(公告)日:2020-07-29
The present disclosure relates to a novel compound as a JAK inhibitor, a composition, and an application thereof. Specifically, the present disclosure provides a compound having high AK inhibitory activity (as represented by formula (I)) or its isomer, solvate, hydrate, pharmaceutically-acceptable salt, and prodrug, and a pharmaceutical composition containing the compound. Also disclosed is an application of the present compound or pharmaceutical composition in preparation of a drug, and the drug is used for treating autoimmune diseases or cancers.
本公开涉及一种作为 JAK 抑制剂的新型化合物、一种组合物及其应用。具体而言,本公开提供了一种具有高 AK 抑制活性的化合物(如式 (I) 所示)或其同分异构体、溶解物、水合物、药学上可接受的盐和原药,以及含有该化合物的药物组合物。还公开了本化合物或药物组合物在制备药物中的应用,该药物用于治疗自身免疫性疾病或癌症。
2-substituted pyrazole amino-4-substituted amino-5-pyrimidine formamide compound, composition, and application thereof
申请人:BEIJING SCITECH-MQ PHARMACEUTICALS LIMITED
公开号:US11344549B2
公开(公告)日:2022-05-31
The present disclosure relates to a novel compound as a JAK inhibitor, a composition, and an application thereof. Specifically, the present disclosure provides a compound having high JAK inhibitory activity (as represented by formula (I)) or its isomer, solvate, hydrate, pharmaceutically-acceptable salt, and prodrug, and a pharmaceutical composition containing the compound. Also disclosed is a use of the present compound or pharmaceutical composition in preparation of a medicament for treating autoimmune diseases or cancers.
本公开涉及一种作为 JAK 抑制剂的新型化合物、一种组合物及其应用。具体而言,本公开提供了一种具有高 JAK 抑制活性的化合物(如式 (I) 所示)或其异构体、溶解物、水合物、药学上可接受的盐和原药,以及含有该化合物的药物组合物。还公开了本化合物或药物组合物在制备治疗自身免疫性疾病或癌症的药物中的用途。
[EN] UREA-SUBSTITUTED AROMATIC RING-LINKED DIOXANE AND QUINAZOLINE OR QUINOLINE COMPOUND, COMPOSITION AND APPLICATION THEREOF<br/>[FR] COMPOSÉ DE DIOXANE ET DE QUINAZOLINE OU DE QUINOLÉINE LIÉ À UN CYCLE AROMATIQUE SUBSTITUÉ PAR URÉE, COMPOSITION ET UTILISATION ASSOCIÉE<br/>[ZH] 脲取代的芳环连二噁烷并喹唑啉或喹啉类化合物、组合物及其应用